MDMA for Soldiers?

pill-x-780px

Could returned servicemen with war-ravaged hearts and minds soon be given MDMA to smooth their way back into society?

Is using MDMA for post-traumatic stress disorder (PTSD) a legitimately good idea, and is it ever going to be common practice? ImportantCool spoke to Dr Stephen Bright of Curtin University to learn more about this Huxley-esque development.

Dr Bright, speaking from Melbourne, is awaiting research ethics clearance to carry out MDMA-assisted psychotherapy with war veterans diagnosed with treatment-resistant PTSD. Following on from pilot studies in the United States, Dr Bright thinks that MDMA, the active ingredient in the drug commonly known as Ecstasy, could be the key to resolving their trauma.

‘In terms of using MDMA in the context of psychotherapy, it’s advantageous for a couple of reasons,’ Dr Bright says. ‘One is that the primary treatment for people with post-traumatic stress disorder is exposure therapy. So, we talk about traumatic experience over and over again and it allows the person to process the trauma. However, that can be very difficult for both the patient and the therapist. Hearing the story over and over again can cause vicarious trauma for the therapist and patients often drop out of the treatment because they find it too difficult to talk about the trauma, or they engage in defense mechanisms to prevent themselves from actually experiencing the level of anxiety that’s required for the therapy to be effective.’

You probably won’t be surprised to hear that this treatment is ineffective for a significant proportion of patients. Depending on who you ask, it seems that between 30 percent and 50 percent of patients do not resolve their PTSD through this form of therapy.

Read the rest of the interview here: http://www.importantcool.com/mdma-soldiers-interview-dr-stephen-bright-mdma-assisted-psychotherapy-ptsd/

Share this post

Innovative psychedelic research

The re-emergence of psychedelic research places a crucial emphasis on a holistic approach to mental health from pharmacology, neurobiological process, ecological connection, and therapeutic support.  PRISM supports research and clinical development of therapies where current options provide limited relief.

Your support allows us to pursue cutting edge research for next-generation mental health care.

PRISM

We are a DGR-1 non-profit research charity developing medical and legal processes for the application of psychedelic medicines for improved wellbeing.

Newsletter

Contact Us

Send us an email and we'll get back to you soon.

Not readable? Change text. captcha txt
0

Start typing and press Enter to search